Abstract
Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of the MET recepto...
Cite
CITATION STYLE
APA
Wolf, J., Seto, T., Han, J.-Y., Reguart, N., Garon, E. B., Groen, H. J. M., … Heist, R. S. (2020). Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer. New England Journal of Medicine, 383(10), 944–957. https://doi.org/10.1056/nejmoa2002787
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free